Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

High Prevalence of Fluoroquinolone-Resistant Group B Streptococci among Clinical Isolates in China and Predominance of Sequence Type 19 with Serotype III

Hui Wang, Chunjiang Zhao, Wenqiang He, Feifei Zhang, Liyan Zhang, Bin Cao, Ziyong Sun, Yingchun Xu, Qing Yang, Yaning Mei, Bijie Hu, Yunzhuo Chu, Kang Liao, Yunsong Yu, Zhidong Hu, Yuxing Ni
Hui Wang
aDepartment of Clinical Laboratory, Peking University People's Hospital, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chunjiang Zhao
aDepartment of Clinical Laboratory, Peking University People's Hospital, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wenqiang He
aDepartment of Clinical Laboratory, Peking University People's Hospital, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Feifei Zhang
aDepartment of Clinical Laboratory, Peking University People's Hospital, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liyan Zhang
bDepartment of Clinical Laboratory, Guangdong General Hospital, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bin Cao
cDepartment of Infectious Diseases and Clinical Microbiology and Beijing Institute of Respiratory Medicine, Beijing ChaoYang Hospital, Capital Medical University, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ziyong Sun
dTongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yingchun Xu
eDepartment of Clinical Laboratory, Peking Union Medical College Hospital, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qing Yang
fThe First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yaning Mei
gDepartment of Clinical Laboratory, Jiangsu General Hospital, Nanjing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bijie Hu
hZhongshan Hospital, Fudan University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yunzhuo Chu
iDepartment of Clinical Laboratory, The First Hospital of China Medical University, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kang Liao
jDepartment of Clinical Laboratory, The First Affiliated Hospital of Sun Yatsen University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yunsong Yu
kSir Run Run Shaw Hospital, Hangzhou University, Hangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhidong Hu
lDepartment of Clinical Laboratory, General Hospital, Tianjin Medical University, Tianjin, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuxing Ni
mDepartment of Clinical Microbiology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.02317-12
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

A total of 146 group B streptococcus isolates from 8 cities across China belonged to four serotypes. Serotype Ia was more common in children. A high prevalence of resistance was observed for levofloxacin (37.7%), erythromycin (71.2%), clindamycin, (53.4%), and tetracycline (81.5%). The levofloxacin and clindamycin resistances among the 4 serotypes differed significantly. Eighty percent of fluoroquinolone-resistant isolates belonged to the sequence type 19 (ST19)/serotype III clone, with GyrA-ParC-ParE triple substitutions. This clone carried the erm(B), mef(E), and tet(M) genes.

TEXT

Group B streptococcus (GBS) is the leading cause of septicemia and meningitis in neonates (1). It is also associated with bacteremia, endocarditis, arthritis, and other infections in nonpregnant women with underlying diseases and in elderly adults (2). Clinical GBS isolates usually remain penicillin susceptible. Considering the 0.7% to 10% incidence of penicillin allergies (3), as well as resistance to erythromycin and clindamycin, fluoroquinolones (FQs) are important alternatives. However, FQ resistance has been reported (4–7).

Ten GBS serotypes, specified by the polysaccharide capsule, are known, and five of these (Ia, Ib, II, III, and V) are included in a vaccine that is in development. A knowledge of serotype distribution will be important for vaccine development. Few studies from mainland China have reported on antimicrobial resistance, serotypes, and molecular epidemiology in GBS. Therefore, investigating the current resistance status in GBS in China is necessary. From September to December 2011, 146 clinical consecutive nonduplicate GBS isolates were collected from 13 teaching hospitals in eight cities in China. All isolates were confirmed for identification at the central laboratory. Confirmation testing was done using a commercial latex agglutination technique (Slidex Strepto B; bioMérieux, Marcy L'Étoile, France) and PCR for the dltS gene.

A multiplex PCR assay containing a mixture of 19 primers was performed as described by Imperi et al. (8). Serotype III was the most prevalent, accounting for 63.7% of the isolates, followed by serotypes Ia (21.9%), II (9.6%), and V (4.8%). These findings are similar to previous reports from North America and Europe (9, 10). Serotype Ia was significantly higher in children than in adults (42.9% versus 23%, respectively; P = 0.0414) (Table 1).

View this table:
  • View inline
  • View popup
Table 1

Serotype distribution of GBS isolates across age groups

The MICs of the antimicrobials were determined using the agar dilution method according to guidelines from the Clinical and Laboratory Standards Institute (CLSI) (11). The antimicrobials used were penicillin, cefaclor, cefuroxime, ceftriaxone, erythromycin, clindamycin, tetracycline (Sigma, St. Louis, MO), levofloxacin (Daiichi Sankyo Pharmaceutical, Japan), and moxifloxacin (Bayer AG, Leverkusen, Germany). The results were analyzed by WHONET 5.6 software and interpreted according to CLSI M100-S22 (12). For statistical analysis, χ2 test or Fisher's exact test was used to analyze the qualitative variables, as appropriate. A P value of <0.05 was considered statistically significant.

All 146 isolates were susceptible to penicillin, cefuroxime, cefaclor, and ceftriaxone. Resistance to erythromycin, clindamycin, and tetracycline was found in 104 (71.2%), 78 (53.4%), and 119 (81.5%) isolates, respectively. Fifty-five isolates (37.7%) were levofloxacin resistant. The levofloxacin resistance rate was significantly higher in urinary tract infection (48.4%, 30/62) than in the other cases and among colonized pregnant women (29.8%, 25/84; P < 0.001). Significant differences were found in levofloxacin and clindamycin resistance among the 4 serotypes (P = 0.0015, P = 0.028, respectively). Levofloxacin resistance was significantly higher in serotype III than in serotypes Ia (P = 0.021) and II (P = 0.0006). Clindamycin resistance was lowest in serotype II (P < 0.05, Table 1).

The resistance determinants for FQ, macrolides and tetracycline were determined. PCR amplification and sequencing of the gyrA, gyrB, parC, and parE genes were performed as previously described (13). The macrolide resistance phenotype was determined using a double-disk test with erythromycin and clindamycin (12). Macrolides and tetracycline resistance genes, including erm(B), erm(A), mef(A/E), tet(M), and tet(O), were detected using PCR as previously described (14–16). The mef(A) and mef(E) were determined by sequencing the 1,431 bp mef(A/E) PCR product. Multilocus sequence typing (MLST) and pulsed-field gel electrophoresis (PFGE) were performed for the FQ-resistant isolates as previously described (17–19).

All 119 tetracycline-resistant isolates carried tet(M), and 4 of these isolates also harbored tet(O). Previous studies also found more than one tet gene in the minority of tetracycline-resistant GBS isolates (20, 21). Seventy-eight of 104 erythromycin-resistant isolates showed cMLSB resistance, and the remaining 26 isolates showed an M resistance phenotype. All 78 cMLSB isolates harbored erm(B), and 45 of these isolates also harbored mef(E). The isolates with the M resistance phenotype carried mef(E).

Six STs and seven PFGE types (14 subtypes) were identified for 55 FQ-resistant isolates. ST19-CC19/serotype III, corresponding to PFGE types A to E, was the most predominant type, accounting for 80.0% of the FQ-resistant isolates (Table 2). ST10 and ST23 were associated with serotype Ia, ST17 with serotype III, and ST1 with serotype V, which are consistent with the previous studies (22).

View this table:
  • View inline
  • View popup
Table 2

Phenotypic and genetic characteristics of 55 levofloxacin-resistant GBS isolates

Of the 51 isolates with 32-μg/ml levofloxacin MICs, 44 belonged to ST19/serotype III. All ST19/serotype III isolates had three amino acid substitutions, and five ST10/Ia isolates and one ST1/V had two substitutions (Table 2). Most of the isolates with 8-μg/ml levofloxacin MICs had only one substitution. The specific GyrA-ParC-ParE triple mutation (S81L in GyrA, S79Y in ParC, and H225Y in ParE) and the GyrA-ParC double mutation (S81L in GyrA and S79F in ParC) both conferred high levels of levofloxacin resistance.

Of the 55 FQ-resistant isolates, 80.0%, 70.9%, and 83.6% were resistant to erythromycin, clindamycin, and tetracycline, respectively. Table 2 shows that 45 tetracycline-resistant isolates possessed tet(M) and 1 possessed both tet(M) and tet(O). Among the 41 erythromycin- and tetracycline-resistant ST19/serotype III isolates, 25 harbored the erm(B), mef(E), and tet(M) genes. All five M-phenotype resistant isolates harbored mef(E) and tet(M) (Table 2).

This is the first study on serotype distribution, antimicrobial resistance, and molecular characterization of GBS isolates in mainland China. In the present study, we found high rates of multiple drug resistance in GBS, including resistance to FQ, macrolides, and tetracycline. The incidence of macrolide resistance of GBS is relatively low in western countries, ranging from 11.5% to 32% (9, 20, 22–24), and higher in Taiwan, at 58.3% (25). The first FQ-resistant GBS was reported in 2003 in Japan (26) at a relatively lower prevalence (27, 28). To our knowledge, the FQ resistance rate in the present study is the highest among the latest reports. With the wide use of empirical FQ in various community-acquired infections, FQ-resistant GBS will be encountered in other regions worldwide.

The present study found that the high prevalence of FQ-resistant GBS was associated with the emergence and spread of multidrug-resistant ST19/serotype III clone. The finding of predominance, multiple sources, and distribution of serotype III/ST19 in eight distant areas suggests that its emergence is affecting the whole country. At least two major lineages of GBS isolates of serotype III, ST17 and ST19, have been reported. ST19/serotype III was reported as the predominant clone in Canada (29) and the United States (30), whereas ST23/serotype Ia and ST17/III are the most prevalent in Portugal, Italy, and Spain (20, 23, 24). However, in the Mediterranean region, ST19 was associated with serotypes Ib, II, III, and IV, which may be ascribed to the horizontal transfer of capsular genes among different clones.

In the present study, the FQ-resistant ST19/serotype III isolates also showed resistance to macrolide and tetracycline. Most of these isolates carried the tet(M), erm(B), and mef(E) genes, which may represent multiple horizontal gene transfer events. Supporting the importance of the mechanism, a Polish study reported the identification of the tet(M) and erm(B) genes on the same conjugative Tn916-family transposons in GBS (21). Further study of genetic mobile elements with resistance determinants in GBS is needed in China.

In summary, clonal expansion of multidrug-resistant ST19/serotype III is the primary cause of the high prevalence of FQ resistance in China, which increases concerns regarding its future global spread. The study data emphasizes the need for careful epidemiologic monitoring of this FQ-resistant clone with erm(B), mef(E), and tet(M) genes in invasive diseases.

ACKNOWLEDGMENTS

This study was partially supported by Program for New Century Excellent Talents in University (NCET-10-0205) and Key Projects in the National Science & Technology Pillar Program (2012EP001002).

FOOTNOTES

    • Received 15 November 2012.
    • Returned for modification 25 December 2012.
    • Accepted 1 January 2013.
    • Accepted manuscript posted online 7 January 2013.
  • Copyright © 2013, American Society for Microbiology. All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Skoff TH,
    2. Farley MM,
    3. Petit S,
    4. Craig AS,
    5. Schaffner W,
    6. Gershman K,
    7. Harrison LH,
    8. Lynfield R,
    9. Mohle-Boetani J,
    10. Zansky S,
    11. Albanese BA,
    12. Stefonek K,
    13. Zell ER,
    14. Jackson D,
    15. Thompson T,
    16. Schrag SJ
    . 2009. Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990–2007. Clin. Infect. Dis. 49:85–92.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Rocchetti T,
    2. Marconi C,
    3. Rall V,
    4. Borges V,
    5. Corrente J,
    6. da Silva M
    . 2011. Group B streptococci colonization in pregnant women: risk factors and evaluation of the vaginal flora. Arch. Gynecol. Obstet. 283:717–721.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Neugut AI,
    2. Ghatak AT,
    3. Miller RL
    . 2001. Anaphylaxis in the united states: an investigation into its epidemiology. Arch. Intern. Med. 161:15–21.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Miro E,
    2. Rebollo M,
    3. Rivera A,
    4. Alvarez MT,
    5. Navarro F,
    6. Mirelis B,
    7. Coll P
    . 2006. Streptococcus agalactiae highly resistant to fluoroquinolones. Enferm. Infecc. Microbiol. Clin. 24:562–563.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Wu H-M,
    2. Janapatla RP,
    3. Ho Y-R,
    4. Hung K-H,
    5. Wu C-W,
    6. Yan J-J,
    7. Wu J-J
    . 2008. Emergence of fluoroquinolone resistance in group B streptococcal isolates in Taiwan. Antimicrob. Agents Chemother. 52:1888–1890.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Nagano N,
    2. Nagano Y,
    3. Toyama M,
    4. Kimura K,
    5. Tamura T,
    6. Shibayama K,
    7. Arakawa Y
    . 2012. Nosocomial spread of multidrug-resistant group B streptococci with reduced penicillin susceptibility belonging to clonal complex 1. J. Antimicrob. Chemother. 67:849–856.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Ecker KL,
    2. Donohue PK,
    3. Kim KS,
    4. Shepard JA,
    5. Aucott SW
    . 2012. The impact of group B streptococcus prophylaxis on late-onset neonatal infections. J. Perinatol. [Epub ahead of print.] doi:10.1038/jp.2012.76.
  8. 8.↵
    1. Imperi M,
    2. Pataracchia M,
    3. Alfarone G,
    4. Baldassarri L,
    5. Orefici G,
    6. Creti R
    . 2010. A multiplex PCR assay for the direct identification of the capsular type (Ia to IX) of Streptococcus agalactiae. J. Microbiol. Methods 80:212–214.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Phares CR,
    2. Lynfield R,
    3. Farley MM,
    4. Mohle-Boetani J,
    5. Harrison LH,
    6. Petit S,
    7. Craig AS,
    8. Schaffner W,
    9. Zansky SM,
    10. Gershman K,
    11. Stefonek KR,
    12. Albanese BA,
    13. Zell ER,
    14. Schuchat A,
    15. Schrag SJ
    . 2008. Epidemiology of invasive group B streptococcal disease in the United States, 1999–2005. JAMA 299:2056–2065.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. van der Mee-Marquet N,
    2. Jouannet C,
    3. Domelier A-S,
    4. Arnault L,
    5. Lartigue M-F,
    6. Quentin R
    . 2009. Genetic diversity of Streptococcus agalactiae strains and density of vaginal carriage. J. Med. Microbiol. 58:169–173.
    OpenUrlCrossRefPubMed
  11. 11.↵
    Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard—eighth edition. CLSI document M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
  12. 12.↵
    Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing: twenty-second informational supplement. CLSI document M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA.
  13. 13.↵
    1. Tazi A,
    2. Gueudet T,
    3. Varon E,
    4. Gilly L,
    5. Trieu-Cuot P,
    6. Poyart C
    . 2008. Fluoroquinolone-resistant group B streptococci in acute exacerbation of chronic bronchitis. Emerg. Infect. Dis. 14:349–350.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Ng LK,
    2. Martin I,
    3. Alfa M,
    4. Mulvey M
    . 2001. Multiplex PCR for the detection of tetracycline resistant genes. Mol. Cell. Probes 15:209–215.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Oster P,
    2. Zanchi A,
    3. Cresti S,
    4. Lattanzi M,
    5. Montagnani F,
    6. Cellesi C,
    7. Rossolini GM
    . 1999. Patterns of macrolide resistance determinants among community-acquired Streptococcus pneumoniae isolates over a 5-year period of decreased macrolide susceptibility rates. Antimicrob. Agents Chemother. 43:2510–2512.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Palmeiro JK,
    2. Dalla-Costa LM,
    3. Fracalanzza SEL,
    4. Botelho ACN,
    5. da Silva Nogueira K,
    6. Scheffer MC,
    7. de Almeida Torres RSL,
    8. de Carvalho NS,
    9. Cogo LL,
    10. Madeira HMF
    . 2010. Phenotypic and genotypic characterization of group B streptococcal isolates in southern Brazil. J. Clin. Microbiol. 48:4397–4403.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Benson JA,
    2. Ferrieri P
    . 2001. Rapid pulsed-field gel electrophoresis method for group B streptococcus isolates. J. Clin. Microbiol. 39:3006–3008.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Jones N,
    2. Bohnsack JF,
    3. Takahashi S,
    4. Oliver KA,
    5. Chan MS,
    6. Kunst F,
    7. Glaser P,
    8. Rusniok C,
    9. Crook DW,
    10. Harding RM,
    11. Bisharat N,
    12. Spratt BG
    . 2003. Multilocus sequence typing system for group B streptococcus. J. Clin. Microbiol. 41:2530–2536.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Tenover FC,
    2. Arbeit RD,
    3. Goering RV,
    4. Mickelsen PA,
    5. Murray BE,
    6. Persing DH,
    7. Swaminathan B
    . 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233–2239.
    OpenUrlFREE Full Text
  20. 20.↵
    1. Gherardi G,
    2. Imperi M,
    3. Baldassarri L,
    4. Pataracchia M,
    5. Alfarone G,
    6. Recchia S,
    7. Orefici G,
    8. Dicuonzo G,
    9. Creti R
    . 2007. Molecular epidemiology and distribution of serotypes, surface proteins, and antibiotic resistance among group B streptococci in Italy. J. Clin. Microbiol. 45:2909–2916.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Sadowy E,
    2. Matynia B,
    3. Hryniewicz W
    . 2010. Population structure, virulence factors and resistance determinants of invasive, non-invasive and colonizing Streptococcus agalactiae in Poland. J. Antimicrob. Chemother. 65:1907–1914.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Murayama SY,
    2. Seki C,
    3. Sakata H,
    4. Sunaoshi K,
    5. Nakayama E,
    6. Iwata S,
    7. Sunakawa K,
    8. Ubukata K
    , the SDW Group. 2009. Capsular type and antibiotic resistance in Streptococcus agalactiae isolates from patients, ranging from newborns to the elderly, with invasive infections. Antimicrob. Agents Chemother. 53:2650–2653.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Martins ER,
    2. Melo-Cristino J,
    3. Ramirez M
    , Portuguese Group for the Study of Streptococcal Infections. 2012. Dominance of serotype Ia among group B streptococci causing invasive infections in nonpregnant adults in Portugal. J. Clin. Microbiol. 50:1219–1227.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Martins ER,
    2. Andreu A,
    3. Correia P,
    4. Juncosa T,
    5. Bosch J,
    6. Ramirez M,
    7. Melo-Cristino J
    . 2011. Group B streptococci causing neonatal infections in Barcelona are a stable clonal population: 18-year surveillance. J. Clin. Microbiol. 49:2911–2918.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Wang Y-H,
    2. Su L-H,
    3. Hou J-N,
    4. Yang T-H,
    5. Lin T-Y,
    6. Chu C,
    7. Chiu C-H
    . 2010. Group B Streptococcal disease in nonpregnant patients: emergence of highly resistant strains of serotype Ib in Taiwan in 2006 to 2008. J. Clin. Microbiol. 48:2571–2574.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Kawamura Y,
    2. Fujiwara H,
    3. Mishima N,
    4. Tanaka Y,
    5. Tanimoto A,
    6. Ikawa S,
    7. Itoh Y,
    8. Ezaki T
    . 2003. First Streptococcus agalactiae isolates highly resistant to quinolones, with point mutations in gyrA and parC. Antimicrob. Agents Chemother. 47:3605–3609.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Biedenbach DJ,
    2. Toleman MA,
    3. Walsh TR,
    4. Jones RN
    . 2006. Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997–2004). Diagn. Microbiol. Infect. Dis. 55:119–127.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Wehbeh W,
    2. Rojas-Diaz R,
    3. Li X,
    4. Mariano N,
    5. Grenner L,
    6. Segal-Maurer S,
    7. Tommasulo B,
    8. Drlica K,
    9. Urban C,
    10. Rahal JJ
    . 2005. Fluoroquinolone-resistant Streptococcus agalactiae: epidemiology and mechanism of resistance. Antimicrob. Agents Chemother. 49:2495–2497.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Manning SD,
    2. Springman AC,
    3. Lehotzky E,
    4. Lewis MA,
    5. Whittam TS,
    6. Davies HD
    . 2009. Multilocus sequence types associated with neonatal group B streptococcal sepsis and meningitis in Canada. J. Clin. Microbiol. 47:1143–1148.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Manning SD,
    2. Lewis MA,
    3. Springman AC,
    4. Lehotzky E,
    5. Whittam TS,
    6. Davies D
    . 2008. Genotypic diversity and serotype distribution of group B streptococcus isolated from women before and after delivery. Clin. Infect. Dis. 46:1829–1837.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
High Prevalence of Fluoroquinolone-Resistant Group B Streptococci among Clinical Isolates in China and Predominance of Sequence Type 19 with Serotype III
Hui Wang, Chunjiang Zhao, Wenqiang He, Feifei Zhang, Liyan Zhang, Bin Cao, Ziyong Sun, Yingchun Xu, Qing Yang, Yaning Mei, Bijie Hu, Yunzhuo Chu, Kang Liao, Yunsong Yu, Zhidong Hu, Yuxing Ni
Antimicrobial Agents and Chemotherapy Feb 2013, 57 (3) 1538-1541; DOI: 10.1128/AAC.02317-12

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
High Prevalence of Fluoroquinolone-Resistant Group B Streptococci among Clinical Isolates in China and Predominance of Sequence Type 19 with Serotype III
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
High Prevalence of Fluoroquinolone-Resistant Group B Streptococci among Clinical Isolates in China and Predominance of Sequence Type 19 with Serotype III
Hui Wang, Chunjiang Zhao, Wenqiang He, Feifei Zhang, Liyan Zhang, Bin Cao, Ziyong Sun, Yingchun Xu, Qing Yang, Yaning Mei, Bijie Hu, Yunzhuo Chu, Kang Liao, Yunsong Yu, Zhidong Hu, Yuxing Ni
Antimicrobial Agents and Chemotherapy Feb 2013, 57 (3) 1538-1541; DOI: 10.1128/AAC.02317-12
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596